SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
NCT07479147
Brain Diseases, Cardiovascular Abnormalities
Taichung, Taiwan
View Trial DetailsNCT Number: NCT07347691
This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the predictive value of an Artificial Intelligence ECG analysis tool, named SmartECG-AF.
Participants will be classified into two groups based on the AI analysis: a "High Risk" group and a "Low to Intermediate Risk" (control) group. The study aims to compare the incidence rate of atrial fibrillation (AF) events over time between these two groups. Additionally, the study will analyze the relationship between the AI-predicted risk levels and the occurrence of major cardiovascular events during the follow-up period.
Interested in participating?
Request Info30 year and older
All sexes
Observational
Korea University Ansan Hospital, Ansan, South Korea
Embolic Stroke of Undetermined Source (ESUS) accounts for a significant proportion of ischemic strokes, and occult Atrial Fibrillation (AF) is considered a major etiology. While Implantable Cardiac Monitors (ICMs) are the gold standard for long-term rhythm monitoring, identifying patients at the highest risk for AF remains a clinical challenge.
This multicenter, prospective study aims to validate the clinical utility of an artificial intelligence-based electrocardiogram analysis algorithm, "SmartECG-AF," in this specific population. The algorithm analyzes 12-lead ECGs recorded during sinus rhythm to detect subtle signs of electrical remodeling associated with paroxysmal AF.
Enrolled patients with ESUS who have undergone ICM implantation will have their baseline ECGs analyzed by the SmartECG-AF algorithm. Based on the AI-generated probability score, patients will be stratified into a "High Risk" group and a "Low to Intermediate Risk" group. The study will longitudinally track these patients to compare the time-to-event for ICM-detected AF between the two groups. Additionally, the study will evaluate the correlation between the AI risk score and the incidence of Major Adverse Cardiovascular Events (MACE), providing evidence for AI-guided risk stratification in cryptogenic stroke management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 12 months
Comparison of the cumulative incidence rate of atrial fibrillation (AF) events between the High Risk group and the Low to Intermediate Risk group (classified by SmartECG-AF). AF occurrence is confirmed by reviewing data recorded on the Implantable Cardiac Monitor (ICM).
Time frame: Up to 12 months
Evaluation of the composite rate of major clinical events including recurrent stroke, hospitalization for heart failure, myocardial infarction, and all-cause death (cardiovascular and non-cardiovascular). The study will analyze the correlation between the occurrence of these events and the AI-predicted risk levels.
Contact information is provided by the study sponsor or research team.
Hyoung Seok Lee, MD
CONTACT
Yong-Soo Baek, MD, PhD
CONTACT
Inha University Hospital
Other
Predicting Atrial Fibrillation in Patients With Post-implantable Cardiac Monitor Implementation : A Prospective, Long-term Follow-up Study Using Comprehensive AI ECG Analysis : Multicenter Prospective Study
Acronym: SMART-ESUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07479147
Brain Diseases, Cardiovascular Abnormalities
Taichung, Taiwan
View Trial DetailsNCT07224178
Brain Diseases, Cardiovascular Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06100718
Brain Diseases, Cancer-related Stroke
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT05044208
Arrhythmias, Cardiac, Atrial Fibrillation
Tulln, Austria
View Trial Details